Search results for " progress"

showing 10 items of 1287 documents

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct

Odontogenic abscess complicated by descending necrotizing mediastinitis: evidence of medical and dental malpractice

2016

Abscess; Adolescent; Dental Caries; Disease Progression; Emergencies; Fatal Outcome; Female; Humans; Italy; Mandibular Diseases; Mediastinitis; Molar; Multiple Organ Failure; Shock Septic; Tomography X-Ray Computed; MalpracticeAdolescentSepticMultiple Organ FailureOtorhinolaryngology2734 Pathology and Forensic MedicineMalpracticeShockDental CariesShock SepticMolarAbscessX-Ray ComputedMediastinitisFatal OutcomeItalyDisease ProgressionHumansSurgeryFemaleMandibular DiseasesOral SurgeryEmergenciesTomography X-Ray ComputedTomography
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

Biological Basis of the HLA-B8,DR3-Associated Progression of Acquired Immune Deficiency Syndrome

1998

The factors influencing the evolution of human immunodeficiency virus (HIV) infection are not fully known, but the host genotype undoubtedly plays a role in determining the outcome of the disease by affecting the immune response to HIV. The role of the host human leukocyte antigen (HLA) genotype in the regulation of susceptibility to HIV infection and expression has been studied extensively in different major risk groups. Certain HLA alleles and haplotypes, being associated with aberrant immune responses independently from HIV infection, have been reported to facilitate the rapid progression of disorders related to HIV infection. Particularly, the association of rapid acquired immunodeficie…

Acquired Immunodeficiency SyndromeGenotypeHuman immunodeficiency virus (HIV)Cell BiologyGeneral MedicineDiseaseBiologymedicine.disease_causemedicine.diseaseVirologyImmune deficiency syndromeHLA-B8 AntigenPathology and Forensic MedicineHLA-DR3 AntigenTh2 CellsHaplotypesAcquired immunodeficiency syndrome (AIDS)ImmunologyDisease ProgressionmedicineHumansDisease SusceptibilityMolecular BiologyHost genotypePathobiology
researchProduct

IMPAIRED ALLOCENTRIC SPATIAL MEMORY UNDERLYNG TOPOGRAPHICAL DISORIENTATION

2006

The cognitive processes supporting spatial navigation are considered in the context of a patient (CF) with possible very early Alzheimer's disease who presents with topographical disorientation. Her verbal memory and her recognition memory for unknown buildings, landmarks and outdoor scenes was intact, although she showed an impairment in face processing. By contrast, her navigational ability, quantitatively assessed within a small virtual reality (VR) town, was significantly impaired. Interestingly, she showed a selective impairment in a VR object-location memory test whenever her viewpoint was shifted between presentation and test, but not when tested from the same viewpoint. We suggest t…

Activities of Daily Living/psychology Aged Alzheimer Disease/diagnosis Alzheimer Disease/physiopathology Alzheimer Disease/psychology Animals Disability Evaluation Disease Progression Early Diagnosis Female Hippocampus/pathology Hippocampus/physiopathology Humans Memory/physiology Memory Disorders/diagnosis Memory Disorders/physiopathology Memory Disorders/psychology Middle Aged Models Neurological Neuropsychological Tests Orientation/physiology Space Perception/physiology Verbal Behavior/physiologySettore M-PSI/02 - Psicobiologia E Psicologia Fisiologica
researchProduct

Not Entirely Reliable: Private Scientific Organizations and Risk Regulation – The Case of Electromagnetic Fields

2013

Private scientific organizations exert a great deal of influence in the regulation of some technological risks. The high level of expertise of their members is arguably a good reason for them to participate in making and monitoring risk regulations, in order to adjust these to scientific progress. Nevertheless, there are also sound reasons why governments shouldn’t uncritically follow the views expressed by such organizations. Taking the role played by the International Commission on Non–Ionizing Radiation Protection in the regulation of electromagnetic fields as an illustrative example, this paper shows that private scientific organizations such as these are structurally less well suited t…

Actuarial scienceOrder (exchange)business.industryScientific progressmedia_common.quotation_subjectCommissionPublic relationsbusinessSafety ResearchLawDemocracymedia_commonRisk regulationEuropean Journal of Risk Regulation
researchProduct

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

2019

Background: TP73 isoforms gained particular relevance in acute promyelocytic leukemia (APL) since Bernasola et al (JEM. 2004) demonstrated that TAp73 was directly regulated by the PML protein in the nuclear body. The isoforms differ in their transcriptional activity, with those lacking domains in the N-terminal part of the protein exerting a dominant negative effect on TP73 function. In a retrospective analysis of patients with APL treated in ICAPL study, Lucena-Araujo et al (Blood 2015) demonstrated the association between higher ΔNp73/TAp73 ratio values and poor clinical outcome. However,there is a diversity of TP73 isoforms and specially those lacking N-terminal domains (e.g.ΔEx2p73, ΔEx…

Acute promyelocytic leukemiaTranscriptional activitymedicine.medical_specialtySupervisory boardbusiness.industryeducationImmunologyDisease progressionCell BiologyHematologyNewly diagnosedmedicine.diseaseBiochemistryFamily medicinemedicineFunctional studiesProtein abundancebusinessHematology+Oncologyhealth care economics and organizationsBlood
researchProduct

TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas.

2006

The putative role of TP53 and p16INK4A tumor suppressor genes and Ras oncogenes in the development and progression of salivary gland neoplasias was studied in 28 cases of pleomorphic adenomas (PA), 4 cases of cystic adenocarcinomas, and 1 case of carcinoma ex-PA. Genetic and epigenetic alterations in the above genes were analyzed by Polymerase Chain Reaction/Single Strand Conformational Polymorphism (PCR/SSCP) and sequencing and by Methylation Specific-PCR (MS-PCR). Mutations in TP53 were found in 14% (4/28) of PAs and in 60% (3/5) of carcinomas. Mutations in H-Ras and K-Ras were identified in4%(1/28) and7% (2/28) of PAs, respectively. Only 20% (1/5) of carcinomas screened displayed mutatio…

AdenomaAdenomaGenotypePhysiologyClinical BiochemistryBiologymedicine.disease_causeMethylationEpigenesis GeneticProto-Oncogene Proteins p21(ras)GenotypemedicineCarcinomaHumansEpigeneticsTP53GeneCyclin-Dependent Kinase Inhibitor p16Base SequenceSingle-strand conformation polymorphismCell BiologyMethylationmedicine.diseaseMolecular biologyCell Transformation NeoplasticMutationDisease ProgressionTumor Suppressor Protein p53Carcinogenesis
researchProduct